CD38 and Miyoshi myopathy: Daratumumab, the first mAb approved for MM, targets CD38 and induces tumor cell death through multiple mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (ADC), and antibody-dependent cellular phagocytosis (ADCP) [125].